Triple PPI therapy approved for new H pylori uses in Japan
This article was originally published in Scrip
Several companies have received regulatory approval in Japan for the concomitant use of their proton pump inhibitors (PPIs) as part of combination therapy for the eradication of Helicobacter pylori infections in three new medical settings.
You may also be interested in...
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.
Join Scrip and the Pink Sheet’s Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.